Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ajog.2005.02.082
DC FieldValue
dc.titleA prospective, randomized comparison of vaginal misoprostol versus intra-amniotic prostaglandins for midtrimester termination of pregnancy
dc.contributor.authorSu, L.-L.
dc.contributor.authorBiswas, A.
dc.contributor.authorChoolani, M.
dc.contributor.authorKalaichelvan, V.
dc.contributor.authorSingh, K.
dc.date.accessioned2011-09-15T08:21:53Z
dc.date.available2011-09-15T08:21:53Z
dc.date.issued2005
dc.identifier.citationSu, L.-L., Biswas, A., Choolani, M., Kalaichelvan, V., Singh, K. (2005). A prospective, randomized comparison of vaginal misoprostol versus intra-amniotic prostaglandins for midtrimester termination of pregnancy. American Journal of Obstetrics and Gynecology 193 (4) : 1410-1414. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ajog.2005.02.082
dc.identifier.issn00029378
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/26002
dc.description.abstractObjective: The purpose of this study was to compare the efficacy and adverse effects of vaginal misoprostol and intra-amniotic PGF2α for midtrimester abortion. Study design: One hundred thirty-two women between 12 and 24 weeks' gestation, seeking abortion in a tertiary hospital, were randomized to receive vaginal misoprostol (400 μg every 3 hours) or intra-amniotic PGF2α (carboprost 1.5 mg). Main outcome measures were induction-to-abortion interval, success rates at 24 and 48 hours, and adverse effects. Results: Successful abortion rates at 24 and 48 hours between intra-amniotic PGF2α and vaginal misoprostol were not statistically different. However, vaginal misoprostol results in a significantly shorter mean induction-to-abortion interval, compared with intra-amniotic PGF2α (misoprostol: 16.2 hours; intra-amniotic PGF 2α: 20.8 hours; P = .006), particularly among multiparous women (misoprostol: 13.1 hours; intra-amniotic PGF2α 18.3 hours; P = .011) and for gestation below 130 days (misoprostol: 14.6 hours; intra-amniotic PGF2α: 20.2 hours; P = .015). Fever and shivering were commoner with vaginal misoprostol. Conclusion: Vaginal misoprostol should be the regimen of choice for midtrimester abortion, particularly for multiparous women and women in the early second trimester. © 2005 Elsevier Inc. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.ajog.2005.02.082
dc.sourceScopus
dc.subjectIntra-amniotic prostaglandins
dc.subjectRandomized, controlled trial
dc.subjectSecond-trimester pregnancy termination
dc.subjectVaginal misoprostol
dc.typeArticle
dc.contributor.departmentOBSTETRICS & GYNAECOLOGY
dc.description.doi10.1016/j.ajog.2005.02.082
dc.description.sourcetitleAmerican Journal of Obstetrics and Gynecology
dc.description.volume193
dc.description.issue4
dc.description.page1410-1414
dc.identifier.isiut000232408000019
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

19
checked on Aug 4, 2020

WEB OF SCIENCETM
Citations

18
checked on Aug 4, 2020

Page view(s)

240
checked on Aug 4, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.